## sanofi

19th February 2025

To, The Secretary BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai 400 001 Scrip Code: 500674

The Secretary National Stock Exchange of India Limited Exchange Plaza, 5th Floor Plot No. C/1, G Block Bandra-Kurla Complex, Bandra East, Mumbai 400 050 Symbol: SANOFI

## Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("SEBI (LODR) Regulations")

Dear Sir/Madam,

In compliance with Regulation 30 of the SEBI (LODR) Regulations, we hereby submit the disclosure regarding Order issued by the Department of Commercial Taxes, Government of Karnataka.

The details of the above notice as required under Regulation 30 of Listing Regulations are given below:

Name of the authority	Assistant Commissioner of Commercial Taxes (Audit) - Department of Commercial Taxes, Government of Karnataka.
Nature and details of the action(s) taken, initiated or order(s) passed	This relates to a show cause notice issued to Sanofi India Limited in Karnataka for FY 2020-21 regarding a GSTR-2A vs. 3B matter. Initially, an ASMT-10 notice was issued alleging a demand of Rs. 39,36,821/- for a mismatch of ITC availed in GSTR-3B as compared to GSTR-2A. Following the submissions and explanations provided, the final demand raised in the show cause notice was for Rs. 3,14,904/-, along with interest and a ten percent penalty. Considering the non-availability of vendor confirmation, the demand was paid vide DRC- 03, amounting to Rs. 5,22,188. Accordingly, the Assistant Commissioner (Jayadeva Hakkali) has issued an order to drop the proceedings under Section 73

## sanofi

Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	18 <sup>th</sup> February 2025
Details of the violation(s)/contravention(s) committed or alleged to be committed;	The proceedings under Section 73 are hereby dropped and concluded.
Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible.	There is no material impact on financial, operational or other activities of the Company.

This is for your information and records.

Thanking you,

Yours faithfully

For Sanofi India Limited

Rachid Ayari Whole-time Director and Chief Financial Officer DIN: 10408699